Dear Sir, Of all solid tumors in humans the molecular carcinogenesis of colorectal cancer (CRC) is one of the best understood. However, the role of alterations of the retinoblastoma susceptibility tumor suppressor gene RB-1 with regard to malignant transformation and metastatic progression of these neoplasms is still poorly comprehended. RB-1 was the first tumor suppressor gene to be discovered and is located on chromosome 13q14. Its overall size amounts to 200 kB of genomic DNA, including 27 exons (4,750 bp), encoding a nuclear phosphoprotein consisting of 928 amino acids (pRB110) that can be detected in all human tissues and is phosphorylated by activated cyclin-dependent kinases during the G1-phase. Recent data suggest that pRB110 may play an important role in switching the cell cycle towards the S-phase by releasing its covalent binding partner, transcription factor E2-F, at the restriction point [1, 2] .
Inherited RB inactivation is associated with the development of retinoblastomas in children. Survivors of inherited retinoblastoma have an increased risk of developing secondary tumors, mainly osteogenic and soft tissue sarcomas. In other tumors, RB-1 inactivation is found with varying frequency. However, there is no doubt that alterations of one or more contributors to the RB-1/E2F pathway (p16, cdk4, RB-1 and E2F) play a crucial role in the majority of human malignancies. This may also apply to CRC: although so far no mutations of RB-1 in colorectal cancer have been reported, various researchers have discussed a putative role of RB alterations in these tumors in the past [3, 4] .
Evidence of the importance of RB-1 alterations in colorectal carcinogenesis was mainly provided by the finding that alterations of allelic copy numbers affecting the RB locus have been found in 30-50% of colorectal cancers. Among those, allelic amplifications that are specific for the genetic location of RB-1 occurred in 10%, whereas the frequency of allelic losses was not increased in most studies [5, 6] . In all CRCs which were analyzed with regard to the number of RB allelic copies, an intact RB transcript could be detected as well as an intact protein, and protein synthesis was increased in some cases. In a certain percentage of colorectal cancers one can also find an altered state of phosphorylation or increased DNA-binding capacity of pRB110, thus leading to the hypothesis of a causal connection between RB allelic multiplications and elevated pRB110 synthesis in colorectal cancer [3, 5, 7, 8] . However, this would be contradictory to previous findings describing RB-1 as a tumor suppressor gene, whose overexpression is not thought to promote malignant transformation, but should instead hamper the growth of cells.
Taken together, available data on RB alterations in colorectal cancer are somewhat confusing, and, in particular, it is still unresolved whether RB-1 exon mutations contribute to colorectal carcinogenesis at all. Remarkably, the authors of one previous study failed to demonstrate mutations of the RB exon 21 (which is coding a part of the RB oncogene binding region) in 6 CRC cell lines by denaturating gel electrophoresis, although alterations in RB allelic copy number had been proven in most of those samples before. On this background, analyzing a larger number of specimens of patients with colorectal cancer may be helpful to answer the question of whether RB-1 mutations actually play a role in colorectal carcinogenesis before further investigations may be proceeded.
Demographic data

Retinoblastoma in Liver Metastases
We therefore performed mutational analysis of RB exons 11-23 by using a 'single-strand conformation polymorphism (SSCP)'-analysis of PCR products (SSCP-PCR) in surgical specimens obtained from 29 patients with colorectal liver metastases, who had undergone hepatic resection between 1989 and 1993. RB exons 11-23 contain the most important protein domains (oncogene binding pockets). We chose liver metastases as an accumulation of genetic abnormalities is generally observed in advanced and metastatic tumors. Four samples of primary colorectal cancer and 2 samples of healthy colon epithelium for reference purposes were also investigated. The patients' characteristics are summarized in table 1.
Tumor preparation, RNA isolation, and first-strand synthesis were performed as described before, as well as a standard PCRapproach of the RB-1 gene [10, 11] . nucleases (Boehringer Mannheim, Germany). In detail, we used Acc1 to cut the RB 1a/b PCR product (419 bp) into two fragments (137 and 282 bp), whereas restriction cut with Bcl1 resulted in a RB2a/b PCR product (483 bp) of two (254 and 229) and those with Mae3 in a RB3/4 PCR product of 3 (265-, 164-and 65-bp) fragments. Gel electrophoresis (2 Ìl restriction product, diluted with 8 Ìl formamide dye) was handled vertically, using Hydrolink Long Ranger (ATBiochem, Malvern, USA)-based electrophoresis gels at polyacrylamide concentrations of 0.5% (RB 2a/b, both fragments; RB 3/4, larger fragments) and 1% (RB1a/b, both fragments; RB 3/4, small fragment), using an electrophoresis running time of 14 h at 8 W for all samples, except for the small RB 3/4-fragment (10 h, 6 W). Autoradiography of electrophoresis gels was performed using an X-ray film sensitive to 32 P (EastmanKodak, New York, N.Y., USA; fig. 1 ).
Cycle sequencing of plasmid DNA was performed after cloning RB templates into a plasmide vector by using the TA cloning kit (Invitrogen, Groningen, The Netherlands). After ligation with the pCR I vector (Invitrogen) by a T4 ligase, transformation of plasmid into Escherichia coli was performed by using 'one-shot' cells. Plasmid DNA was extracted from overnight cultures by using the QIAprep-plasmid Mini-kit (Qiagen, Hilden, Germany) before cycle sequencing (25 cycles at 96°C/30 s, 50°C/15 s, and 60°C/4 s) with 5 Ìl template (approximately 1 Ìg DNA) was initiated using the PRISM Ready reaction Dyedesoxy-Terminator Cycle Sequencing Kit (Applied Biosystems, Weiterstadt, Germany). Unincorporated redundant molecules of the dye were separated from the extension product by means of Sephadex column chromatography (Amersham, Braunschweig, Germany). Electrophoretic separation was performed in a semiautomatic sequencer under denaturating conditions on a 6% polyacrylamide gel containing urea (model 373 A, Applied Biosystems). In total, sequencing was performed in four plasmids of both of the suspicous samples, respectively, and one control probe, and each plasmid was sequenced in both orientations.
Using the SSCP-PCR approach, we found electrophoretical characteristics differing from the other samples and negative controls in 2 of the 29 samples (7%; fig. 2 ). These 2 samples were from liver metastases of 1 cecum and 1 sigma carcinoma. In sample 11 (patient 27; liver metastasis of a carcinoma of the sigmoid flexure) two parts and in sample 12 (patient 32; liver metastasis of a cecum carcinoma) one part of a band of the biggest fragment of RB 3/4 were missing. As cycle sequencing did not reveal RB mutations in these samples, SSCP-PCR of samples 11 and 12 was repeated, but the previously demonstrated electrophoretic mobility shifts could not be reproduced. Thus we assume that the alterations seen in the first experiment were artifacts due to temperature fluctuations between the electrophoresis gel and the glass top of the electrophoresis apparatus. This phenomenon is predescribed in the context of the separation of DNA molecules over a long distance between the two. Remarkably, both alterations were found in the 265-bp fragment of RB 3/4, which has a long running distance, indeed.
From these results we conclude that RB mutations are not a common event in advanced CRC, and thus do not play an important role in the development and metastatic progression of these neoplasms. Furthermore, these findings suggest, that the allelic changes of RB-1 in CRC described by others are not associated with mutations of functionally relevant exons.
